DCTH

Delcath Systems, Inc. (DCTH) - 2024 Annual Report Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2024. Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic liver cancers. The company operates as a single segment. Its lead product, HEPZATO KIT, received FDA approval in August 2023 for metastatic uveal melanoma (mUM) and began commercial use in the U.S. in January 2024. In Europe, the company markets CHEMOSAT, a medical device for hepatic perfusion, which received MDR certification in February 2022.

Key Financial Metrics

Note: The 2024 Net Loss includes a non-cash charge of approximately $14.1 million related to the change in fair value of warrant liabilities and final valuation upon exercise.

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased by 1,699% to $37.2 million, driven primarily by the commercial launch of HEPZATO KIT in the U.S. ($32.3 million) and increased demand for CHEMOSAT in Europe ($4.9 million).
• Debt Elimination: The company paid off all outstanding debt, including the Avenue Loan and Rosalind Notes, during 2024. Total debt on the balance sheet is now zero.
• Improved Liquidity: Cash and cash equivalents increased by 156% to $32.4 million, bolstered by product revenue and proceeds from warrant exercises and a private placement.
• Expense Management: Research and Development (R&D) expenses decreased by 21% to $13.9 million due to lower NDA submission costs, while Selling, General, and Administrative (SG&A) expenses increased by 34% to $29.6 million to support commercial launch activities.

Guidance, Outlook, and Risks

Outlook and Clinical Pipeline:

• The company expects current cash resources to support operations for at least 12 months from the filing date.
• Colorectal Cancer: An IND for a Phase 2 trial of HEPZATO in combination with standard of care for liver-dominant metastatic colorectal cancer (mCRC) was cleared by the FDA in December 2024. Enrollment is expected to begin in the second half of 2025, with primary readout anticipated by the end of 2027.
• Breast Cancer: A study evaluating HEPZATO for liver-dominant metastatic breast cancer is planned to begin in 2025.
• Reimbursement: CMS established a permanent J-Code for HEPZATO (effective April 2024) and granted New Technology Add-on Payment (NTAP) status (effective October 2024).

• Supply Chain: The company relies on a single contracted supplier for melphalan, a critical component of HEPZATO. Disruptions could halt commercialization.
• Profitability: The company has a history of losses and a substantial accumulated deficit ($531.5 million). Continued profitability depends on scaling HEPZATO sales and expanding indications.
• Reimbursement Uncertainty: While U.S. reimbursement codes are established, European reimbursement for CHEMOSAT varies by country and is not guaranteed.
• Legal: A settlement with former distributor medac GmbH requires ongoing royalty or minimum annual payments, estimated at $1.0 million remaining liability as of year-end.

Investor Verification Checklist

• Revenue Sustainability: Verify the rate of HEPZATO adoption at the 14 active U.S. sites and the conversion of consignment inventory to recognized revenue.
• Supply Chain Security: Confirm the status of discussions with alternative melphalan suppliers to mitigate single-source risk.
• Cash Burn Rate: Monitor operating cash flow to ensure the $53.2 million in liquid assets (cash + short-term investments) is sufficient to fund the planned Phase 2 trials without immediate dilution.
• Reimbursement Expansion: Track the progress of reimbursement applications in key European markets and private payer coverage in the U.S.
• Warrant Liability Impact: Note that the 2024 net loss was significantly impacted by non-cash warrant valuation adjustments; assess future earnings quality excluding these items.